The Application Value of CT Three-Dimensional Microscope Reconstruction Technology in the Diagnosis of Cervical Cancer.

In order to study the application value of CT three-dimensional microscope reconstruction technology in the diagnosis of cervical cancer. In this paper, 232 patients with newly diagnosed stage IA-II A2 and some stage III C: cervical cancer (stage IB1-IIA2 of stage f go in 2009) were selected, and 204 patients with stage IB1-IIA2 of stage 2009 fig 0 were selected. The original data of DICOM were obtained by CT scanning and imported into mics10.01 software to complete lymph node reconstruction. The short diameter value > 10 mm is used as the standard to judge whether the lymph node is metastatic. Referring to the 2018fig 0 staging standard, if it indicates that the lymph node is positive, it is IIICr stage. The gold standard is the diagnosis of III CP according to the surgical and pathological results, and then the diagnostic efficiency of III C stage is evaluated. The experimental results showed that 65 cases were diagnosed as IIIC stage, and 70 cases were diagnosed as IIICp stage. There was consistency between IIICr and IIICp stage, and the kappa value was 0.340. Using CT multiphase enhanced scanning and three-dimensional reconstruction technology to diagnose cervical cancer has high detection rate and high accuracy of staging diagnosis, which is worthy of clinical application.

Overexpressed microRNA-103a-3p inhibits acute lower-extremity deep venous thrombosis via inhibition of CXCL12.

Studies have shown that microRNAs (miRNAs) participate in almost all pathological and physiological processes including acute lower-extremity deep venous thrombosis (LEDVT). Here, this study was designed to elucidate the possible function of miR-103a-3p in acute LEDVT. Expression of miR-103a-3p and chemokine C-X-C motif ligand 12 (CXCL12) was initially quantified in plasma collected from 81 LEDVT patients. Then LEDVT mouse models were established by injection with 3% sodium pentobarbital. The interaction between miR-103a-3p and CXCL12 was identified by dual-luciferase reporter gene assay. After gain- and loss-of-function studies, interleukin-6 (IL-6) and IL-8 and tissue factor (TF) levels, and expression of plasminogen activator inhibitors (PAIs), von Willebrand factor (vWF), thromboxane A2 (TH-A2), F4/80, IL-12, Arginase-1 (Arg-1) and CD206 were determined using enzyme-linked immunosorbent assay (ELISA), reverse transcription quantitative polymerase chain reaction (RT-qPCR) and western blot analysis, respectively. miR-103a-3p was downregulated, while CXCL12 was upregulated in patients and mice with LEDVT. miR-103a-3p targets CXCL12 and inhibited its expression. Overexpressed miR-103a-3p or downregulated CXCL12 decreased expression of IL-6, IL-8, TF, PAIs, vWF, TH-A2, M1 markers (IL-6 and IL-12), yet increased expression of M2 markers (Arg-1 and CD206) in LEDVT mice. Additionally, upregulated miR-103a-3p or silencing CXCL12 suppressed thrombosis in LEDVT mice. However, overexpression of CXCL12 reversed the tendency mentioned above. Altogether, miR-103a-3p can potentially downregulate CXCL12 expression to disrupt inflammatory response and thrombosis, ultimately preventing the development of LEDVT. Our findings underscore a possible alternative therapeutic strategy to limit LEDVT.

Robot-assisted laparoscope fundoplication for gastroesophageal reflux disease: a systematic review of randomized controlled trials.

OBJECTIVE: To evaluate the efficacy and safety of robot-assisted fundoplication (RAF) for treating gastroesophageal reflux disease (GERD). METHODS: Randomized controlled trials (RCTs) or quasi-RCTs were searched for in PubMed, EMBASE, the Cochrane Library, SCI, Chinese Biomedical Database, China Academic Journals Full-Text Database, Chinese Scientific Journals Database, China online journals, and related journals. We evaluated the quality of the included studies by using the 5.0.1 Cochrane Handbook standards and analyzed the data using the Cochrane Collaboration's RevMan 5.0. RESULTS: Five studies (n = 181) were included. A meta-analysis showed that besides the time taken to carry out fundoplication (p < 0.00001), both RAF and conventional laparoscopic fundoplication (CLF) were similar in postoperative antisecretory medication (p = 1.0), intraoperative conversion to open surgery (p = 0.94), postoperative dysphagia (p = 1.0), pneumothorax (p = 1.0), total intraoperative complications (p = 0.24), the time of hiatal dissection (p = 0.98), the time of incision to completion of sutures (p = 0.95), total operation time (p = 0.16), hospital stay (p = 0.97), and total cost (p = 0.25). CONCLUSIONS: The current evidence demonstrates that RAF is safe and effective in treating GERD. The weakness of this treatment method is that it prolongs the time necessary to carry out fundoplication. However, RAF should be the future trend for treating GERD.

Three-port versus four-port laparoscopic cholecystectomy: meta-analysis of randomized clinical trials.

BACKGROUND: Since the first laparoscopic cholecystectomy was reported, the four-trocar laparoscope has become the golden standard procedure. Some surgeons, however, thought that the three-port technique may be safe, effective, and economic. Our meta-analysis compared the three-port technique to the four-port technique. METHODS: We searched the Cochrane Library, MEDLINE, EMBASE, and Chinese Biomedical Literature Database. Quality assessment and data extraction were done by two reviewers independently. The statistical analysis was performed by RevMan4.2.10 software. RESULTS: A total of five publications comprising 591 patients met the inclusion criteria. The result showed that three-port technique could not reduce the analgesia requirements: the sample mean difference (SMD) and 95% confidence interval (CI) were -0.28 (-0.66, 0.10). There were no significant differences between the two groups in terms of operating time [weighted mean difference (WMD) = 2.08, 95% CI (-3.63, 7.79)], success rate [odds ratio (OR) = 0.99,95% CI (0.31, 3.12)], or postoperative hospital stay [OR = -0.52,95% CI (-1.22, 0.17)]. CONCLUSIONS: The current evidence showed that the two groups had similar operating times, success rates, analgesia requirements, and postoperative hospital stays. The methodological qualities of studies are not high, so more high-quality studies are needed for further analysis.

Intravenous pantoprazole as an adjuvant therapy following successful endoscopic treatment for peptic ulcer bleeding.

BACKGROUND: Several studies have suggested that proton pump inhibitors are efficacious in preventing rebleeding when administered immediately after endoscopic treatments. However, there are limited clinical outcome data on the use of intravenous pantoprazole. OBJECTIVE: To evaluate the efficacy of intravenous pantoprazole after successful endoscopic treatment for peptic ulcer bleeding using evidence from randomized controlled trials (RCTs). METHODS: The Cochrane Library, MEDLINE, EMBASE and several Chinese databases up to July 2008 were searched. RCTs that compared the relative effectiveness of intravenous pantoprazole with placebo, H2 receptor antagonist or other agents for patients with peptic ulcer bleeding who were pretreated with successful endoscopic therapies were retrieved. RESULTS: Five RCTs comprising a total of 821 participants were included in the final meta-analysis. Overall, there were significant differences in ulcer rebleeding (RR 0.31; 95% CI 0.18 to 0.53; pooled rates were 4.7% for pantoprazole and 15.0% for control), surgical intervention (RR 0.28, 95% CI 0.09 to 0.83; pooled rates were 1.4% in pantoprazole group versus 6.5% in control) and total length of hospital stay (weighted mean difference -1.53; 95% CI -1.91 to -1.16), but not on mortality (RR 0.72, 95% CI 0.29 to 1.81; pooled mortality rates were 1.9% for pantoprazole versus 2.8% for control) and blood transfusion requirements (weighted mean difference -0.53; 95% CI for random effects -1.04 to -0.02) when compared with control treatments. A series of subgroup analyses supported the results from the main analysis. CONCLUSIONS: Intravenous administration of pantoprazole after endoscopic therapy for peptic ulcer bleeding reduces rates of ulcer rebleeding, surgical intervention and overall duration of hospital stay, but not mortality and blood transfusion requirements compared with placebo, H2 receptor antagonist or somatostatin.

Probiotics in patients with severe acute pancreatitis: a meta-analysis.

BACKGROUND: This study focuses on probiotics in patients with severe acute pancreatitis. It assesses whether enteral feeding with probiotics use reduces infected necrosis and death in severe acute pancreatitis. MATERIALS AND METHODS: We searched the Cochrane Library, Medline, Embase, and Chinese Biomedicine Database. Quality assessment and data extraction were done by two reviewers independently. The statistical analysis was performed by RevMan4.2.10 software. The result was expressed with odds ratio (OR) for the categorical variable. RESULTS: Four studies were included. The result showed that using probiotics could not reduce the risk of infection pancreatic necrosis (OR = 0.56, 95% CI [0.13, 2.35]). There is no significant difference between the two groups in mortality (OR = 0.83, 95% CI [0.14, 4.83]), the mean duration of hospital (WMD = -1.20, 95% CI [-13.13, 10.92]) and the required operation (OR = 0.59, 95% CI [0.11, 3.07]). CONCLUSION: The present study showed the enteral feeding with probiotic could not reduce the infected necrosis and mortality. Future large-scale, high-quality, placebo-controlled, double-blind trials are needed.